Drug intelligence / Profile preview

rM28

Development stage: Phase 2
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

rM28 is a recombinant bispecific single-chain antibody designed to enhance cytotoxic T-cell recognition of melanoma cells by targeting both CD28 and MAPK. This mechanism may improve the immune response against melanoma.

Targets

CD28 (Cluster of Differentiation 28)MAPK3 (Mitogen-activated protein kinase 1)

Beyond the preview

Go deeper on rM28.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rM28.